Perifosine – a new option in treatment of acute myeloid leukemia?

Bibliography

• National cancer Institue. Seer stat fact sheets: Acute myeloid leukemia. Available from: http://seercancergov/statfacts/html/amylhtml [Accessed 14 February 2013]
   Google Scholar
• Haferlach T. Molecular genetic pathways as therapeutic targets in acute myeloid leukemia. Hematol Am Soc Hematol Educ Program 2008;400-11
   PubMedGoogle Scholar
• Brennan P, Mehl AM, Jones M, et al. Phosphatidylinositol 3-kinase is essential for the proliferation of lymphoblastoid cells. Oncogene 2002;21(8):1263-71
   PubMed Web of Science ®Google Scholar
• Yuan TL, Cantley LC. Pi3k pathway alterations in cancer: variations on a theme. Oncogene 2008;27(41):5497-510
   PubMed Web of Science ®Google Scholar
• Pardee AB. Tumor progression--targets for differential therapy. J Cell Physiol 2006;209(3):589-91
   PubMed Web of Science ®Google Scholar
• Sugimoto Y, Whitman M, Cantley LC, et al. Evidence that the rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol. Proc Natl Acad Sci USA 1984;81(7):2117-21
   PubMed Web of Science ®Google Scholar
• Leevers SJ, Vanhaesebroeck B, Waterfield MD. Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol 1999;11(2):219-25
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Leevers SJ, Panayotou G, et al. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci 1997;22(7):267-72
   PubMed Web of Science ®Google Scholar
• Giordanetto F, Wallberg A, Cassel J, et al. Discovery of 4-morpholino-pyrimidin-6-one and 4-morpholino-pyrimidin-2-one-containing phosphoinositide 3-kinase (pi3k) p110beta isoform inhibitors through structure-based fragment optimisation. Bioorg Med Chem Lett 2012;22(21):6665-70
   PubMed Web of Science ®Google Scholar
• Domin J, Gaidarov I, Smith ME, et al. The class ii phosphoinositide 3-kinase pi3k-c2alpha is concentrated in the trans-golgi network and present in clathrin-coated vesicles. The J Biol Chem 2000;275(16):11943-50
   PubMed Web of Science ®Google Scholar
• Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7(8):606-19
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase akt pathway in human cancer. Nat Rev Cancer 2002;2(7):489-501
   PubMed Web of Science ®Google Scholar
• Carpenter CL, Duckworth BC, Auger KR, et al. Purification and characterization of phosphoinositide 3-kinase from rat liver. J biol Chem 1990;265(32):19704-11
   PubMed Web of Science ®Google Scholar
• Martelli AM, Evangelisti C, Chiarini F, et al. Targeting the pi3k/akt/mtor signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs 2009;18(9):1333-49
   PubMed Web of Science ®Google Scholar
• Chan TO, Rittenhouse SE, Tsichlis PN. Akt/pkb and other d3 phosphoinositide-regulated kinases: Kinase activation by phosphoinositide-dependent phosphorylation. Ann Rev Biochem 1999;68:965-1014
   PubMed Web of Science ®Google Scholar
• Ellenbroek SI, Collard JG. Rho gtpases: functions and association with cancer. Clin Exp Metastasis 2007;24(8):657-72
   PubMed Web of Science ®Google Scholar
• Chung J, Kuo CJ, Crabtree GR, et al. Rapamycin-fkbp specifically blocks growth-dependent activation of and signaling by the 70 kd s6 protein kinases. Cell 1992;69(7):1227-36
   PubMed Web of Science ®Google Scholar
• Yamasaki T, Takahashi A, Pan J, et al. Phosphorylation of activation transcription factor-2 at serine 121 by protein kinase c controls c-jun-mediated activation of transcription. J Biol Chem 2009;284(13):8567-81
   PubMed Web of Science ®Google Scholar
• Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of bad couples survival signals to the cell-intrinsic death machinery. Cell 1997;91(2):231-41
   PubMed Web of Science ®Google Scholar
• Zhao S, Konopleva M, Cabreira-Hansen M, et al. Inhibition of phosphatidylinositol 3-kinase dephosphorylates bad and promotes apoptosis in myeloid leukemias. Leukemia 2004;18(2):267-75
   PubMed Web of Science ®Google Scholar
• Hay N. The akt-mtor tango and its relevance to cancer. Cancer Cell 2005;8(3):179-83
   PubMed Web of Science ®Google Scholar
• Fu L, Kim YA, Wang X, et al. Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mtor axis and induces autophagy. Cancer Res 2009;69(23):8967-76
   PubMed Web of Science ®Google Scholar
• Gingras AC, Kennedy SG, O'Leary MA, et al. 4e-bp1, a repressor of mrna translation, is phosphorylated and inactivated by the akt(pkb) signaling pathway. Genes Dev 1998;12(4):502-13
   PubMed Web of Science ®Google Scholar
• Hara K, Yonezawa K, Weng QP, et al. Amino acid sufficiency and mtor regulate p70 s6 kinase and eif-4e bp1 through a common effector mechanism. J Biol Chem 1998;273(23):14484-94
   PubMed Web of Science ®Google Scholar
• McLeod LE, Proud CG. Atp depletion increases phosphorylation of elongation factor eef2 in adult cardiomyocytes independently of inhibition of mtor signalling. FEBS Lett 2002;531(3):448-52
   PubMed Web of Science ®Google Scholar
• Armengol G, Rojo F, Castellvi J, et al. 4e-binding protein 1: A key molecular “funnel factor” in human cancer with clinical implications. Cancer Res 2007;67(16):7551-5
   PubMed Web of Science ®Google Scholar
• Barlund M, Forozan F, Kononen J, et al. Detecting activation of ribosomal protein s6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst 2000;92(15):1252-9
   PubMed Web of Science ®Google Scholar
• Nakamura JL, Garcia E, Pieper RO. S6k1 plays a key role in glial transformation. Cancer Res 2008;68(16):6516-23
   PubMed Web of Science ®Google Scholar
• Nyakern M, Cappellini A, Mantovani I, et al. Synergistic induction of apoptosis in human leukemia t cells by the akt inhibitor perifosine and etoposide through activation of intrinsic and fas-mediated extrinsic cell death pathways. Mol Cancer Ther 2006;5(6):1559-70
   PubMed Web of Science ®Google Scholar
• Brennan P, Babbage JW, Burgering BM, et al. Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator e2f. Immunity 1997;7(5):679-89
   PubMed Web of Science ®Google Scholar
• Chang F, Lee JT, Navolanic PM, et al. Involvement of pi3k/akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003;17(3):590-603
   PubMed Web of Science ®Google Scholar
• Chappell WH, Steelman LS, Long JM, et al. Ras/raf/mek/erk and pi3k/pten/akt/mtor inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011;2(3):135-64
   PubMedGoogle Scholar
• Murga C, Laguinge L, Wetzker R, et al. Activation of akt/protein kinase b by g protein-coupled receptors. A role for alpha and beta gamma subunits of heterotrimeric g proteins acting through phosphatidylinositol-3-oh kinasegamma. J Biol Chem 1998;273(30):19080-5
   PubMed Web of Science ®Google Scholar
• Koch A, Mancini A, El Bounkari O, et al. The sh2-domian-containing inositol 5-phosphatase (ship)-2 binds to c-met directly via tyrosine residue 1356 and involves hepatocyte growth factor (hgf)-induced lamellipodium formation, cell scattering and cell spreading. Oncogene 2005;24(21):3436-47
   PubMed Web of Science ®Google Scholar
• Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296(5573):1655-7
   PubMed Web of Science ®Google Scholar
• Chaurio RA, Janko C, Munoz LE, et al. Phospholipids: key players in apoptosis and immune regulation. Molecules 2009;14(12):4892-914
   PubMed Web of Science ®Google Scholar
• Pike LJ. The challenge of lipid rafts. J Lipid Res 2009;50(Suppl):S323-8
   PubMed Web of Science ®Google Scholar
• Pike LJ. Rafts defined: a report on the keystone symposium on lipid rafts and cell function. J Lipid Res 2006;47(7):1597-8
   PubMed Web of Science ®Google Scholar
• Gao X, Zhang J. Spatiotemporal analysis of differential akt regulation in plasma membrane microdomains. Mol Biol Cell 2008;19(10):4366-73
   PubMed Web of Science ®Google Scholar
• Cully M, You H, Levine AJ, et al. Beyond pten mutations: the pi3k pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006;6(3):184-92
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Chappell WH, et al. Mutations and deregulation of ras/raf/mek/erk and pi3k/pten/akt/mtor cascades which alter therapy response. Oncotarget 2012;3(9):954-87
   PubMedGoogle Scholar
• Taylor V, Wong M, Brandts C, et al. 5′ phospholipid phosphatase ship-2 causes protein kinase b inactivation and cell cycle arrest in glioblastoma cells. Mol Cell Biol 2000;20(18):6860-71
   PubMed Web of Science ®Google Scholar
• Luo JM, Yoshida H, Komura S, et al. Possible dominant-negative mutation of the ship gene in acute myeloid leukemia. Leukemia 2003;17(1):1-8
   PubMed Web of Science ®Google Scholar
• West KA, Castillo SS, Dennis PA. Activation of the pi3k/akt pathway and chemotherapeutic resistance. Drug Resist Updat 2002;5(6):234-48
   PubMed Web of Science ®Google Scholar
• Plo I, Bettaieb A, Payrastre B, et al. The phosphoinositide 3-kinase/akt pathway is activated by daunorubicin in human acute myeloid leukemia cell lines. FEBS Lett 1999;452(3):150-4
   PubMed Web of Science ®Google Scholar
• Tamburini J, Elie C, Bardet V, et al. Constitutive phosphoinositide 3-kinase/akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood 2007;110(3):1025-8
   PubMed Web of Science ®Google Scholar
• Billottet C, Grandage VL, Gale RE, et al. A selective inhibitor of the p110delta isoform of pi 3-kinase inhibits aml cell proliferation and survival and increases the cytotoxic effects of vp16. Oncogene 2006;25(50):6648-59
   PubMed Web of Science ®Google Scholar
• Polak R, Buitenhuis M. The pi3k/pkb signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia. Blood 2012;119(4):911-23
   PubMed Web of Science ®Google Scholar
• Sujobert P, Bardet V, Cornillet-Lefebvre P, et al. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 2005;106(3):1063-6
   PubMed Web of Science ®Google Scholar
• Xu Q, Simpson SE, Scialla TJ, et al. Survival of acute myeloid leukemia cells requires pi3 kinase activation. Blood 2003;102(3):972-80
   PubMed Web of Science ®Google Scholar
• Birkenkamp KU, Geugien M, Schepers H, et al. Constitutive nf-kappab DNA-binding activity in aml is frequently mediated by a ras/pi3-k/pkb-dependent pathway. Leukemia 2004;18(1):103-12
   PubMed Web of Science ®Google Scholar
• Steelman LS, Pohnert SC, Shelton JG, et al. Jak/stat, raf/mek/erk, pi3k/akt and bcr-abl in cell cycle progression and leukemogenesis. Leukemia 2004;18(2):189-218
   PubMed Web of Science ®Google Scholar
• Minami Y, Yamamoto K, Kiyoi H, et al. Different antiapoptotic pathways between wild-type and mutated flt3: insights into therapeutic targets in leukemia. Blood 2003;102(8):2969-75
   PubMed Web of Science ®Google Scholar
• Kindler T, Lipka DB, Fischer T. Flt3 as a therapeutic target in aml: still challenging after all these years. Blood 2010;116(24):5089-102
   PubMed Web of Science ®Google Scholar
• Beghini A, Bellini M, Magnani I, et al. Sti 571 inhibition effect on kitasn822lys-mediated signal transduction cascade. Exp Hematol 2005;33(6):682-8
   PubMed Web of Science ®Google Scholar
• Choudhary C, Schwable J, Brandts C, et al. Aml-associated flt3 kinase domain mutations show signal transduction differences compared with flt3 itd mutations. Blood 2005;106(1):265-73
   PubMed Web of Science ®Google Scholar
• Larizza L, Magnani I, Beghini A. The kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia. Leuk Lymphoma 2005;46(2):247-55
   PubMed Web of Science ®Google Scholar
• Cheong JW, Eom JI, Maeng HY, et al. Phosphatase and tensin homologue phosphorylation in the c-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome. Br J Haematol 2003;122(3):454-6
   PubMed Web of Science ®Google Scholar
• Guthridge MA, Stomski FC, Thomas D, et al. Mechanism of activation of the gm-csf, il-3, and il-5 family of receptors. Stem Cells 1998;16(5):301-13
   PubMed Web of Science ®Google Scholar
• Brandts CH, Sargin B, Rode M, et al. Constitutive activation of akt by flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res 2005;65(21):9643-50
   PubMed Web of Science ®Google Scholar
• Min YH, Eom JI, Cheong JW, et al. Constitutive phosphorylation of akt/pkb protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 2003;17(5):995-7
   PubMed Web of Science ®Google Scholar
• O'Gorman DM, McKenna SL, McGahon AJ, et al. Sensitisation of hl60 human leukaemic cells to cytotoxic drug-induced apoptosis by inhibition of pi3-kinase survival signals. Leukemia 2000;14(4):602-11
   PubMed Web of Science ®Google Scholar
• Grandage VL, Gale RE, Linch DC, et al. Pi3-kinase/akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via nf-kappab, mapkinase and p53 pathways. Leukemia 2005;19(4):586-94
   PubMed Web of Science ®Google Scholar
• Bortul R, Tazzari PL, Billi AM, et al. Deguelin, a pi3k/akt inhibitor, enhances chemosensitivity of leukaemia cells with an active pi3k/akt pathway. Br J Haematol 2005;129(5):677-86
   PubMed Web of Science ®Google Scholar
• Barragan M, Bellosillo B, Campas C, et al. Involvement of protein kinase c and phosphatidylinositol 3-kinase pathways in the survival of b-cell chronic lymphocytic leukemia cells. Blood 2002;99(8):2969-76
   PubMed Web of Science ®Google Scholar
• Ringshausen I, Schneller F, Bogner C, et al. Constitutively activated phosphatidylinositol-3 kinase (pi-3k) is involved in the defect of apoptosis in b-cll: association with protein kinase cdelta. Blood 2002;100(10):3741-8
   PubMed Web of Science ®Google Scholar
• de Frias M, Iglesias-Serret D, Cosialls AM, et al. Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Haematologica 2009;94(12):1698-707
   PubMed Web of Science ®Google Scholar
• Zhuang J, Hawkins SF, Glenn MA, et al. Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of akt inhibition. Haematologica 2010;95(1):110-18
   PubMed Web of Science ®Google Scholar
• Mollinedo F, de la Iglesia-Vicente J, Gajate C, et al. In vitro and in vivo selective antitumor activity of edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. Clin Cancer Res 2010;16(7):2046-54
   PubMed Web of Science ®Google Scholar
• Kondapaka SB, Singh SS, Dasmahapatra GP, et al. Perifosine, a novel alkylphospholipid, inhibits protein kinase b activation. Mol Cancer Ther 2003;2(11):1093-103
   PubMed Web of Science ®Google Scholar
• Clive S, Gardiner J, Leonard RC. Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. Cancer Chemother Pharmacol 1999;44 Suppl:S29-30
   PubMed Web of Science ®Google Scholar
• Dorlo TP, Balasegaram M, Beijnen JH, et al. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother 2012;67(11):2576-97
   PubMed Web of Science ®Google Scholar
• Fei HR, Chen G, Wang JM, et al. Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of akt phosphorylation. Cytotechnology 2010;62(5):449-60
   PubMed Web of Science ®Google Scholar
• Gills JJ, Dennis PA. Perifosine: update on a novel akt inhibitor. Curr Oncol Rep 2009;11(2):102-10
   PubMed Web of Science ®Google Scholar
• Pinton G, Manente AG, Angeli G, et al. Perifosine as a potential novel anti-cancer agent inhibits egfr/met-akt axis in malignant pleural mesothelioma. PLoS ONE 2012;7(5):e36856
   PubMedGoogle Scholar
• Chiarini F, Del Sole M, Mongiorgi S, et al. The novel akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates p-glycoprotein expression in multidrug-resistant human t-acute leukemia cells by a jnk-dependent mechanism. Leukemia 2008;22(6):1106-16
   PubMed Web of Science ®Google Scholar
• Tazzari PL, Tabellini G, Ricci F, et al. Synergistic proapoptotic activity of recombinant trail plus the akt inhibitor perifosine in acute myelogenous leukemia cells. Cancer Res 2008;68(22):9394-403
   PubMed Web of Science ®Google Scholar
• Vink SR, Lagerwerf S, Mesman E, et al. Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts. Clin Cancer Res 2006;12(5):1615-22
   PubMed Web of Science ®Google Scholar
• Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006;107(10):4053-62
   PubMed Web of Science ®Google Scholar
• Celeghini C, Voltan R, Rimondi E, et al. Perifosine selectively induces cell cycle block and modulates retinoblastoma and e2f1 protein levels in p53 mutated leukemic cell lines. Invest New Drugs 2011;29(2):392-5
   PubMed Web of Science ®Google Scholar
• Papa V, Tazzari PL, Chiarini F, et al. Proapoptotic activity and chemosensitizing effect of the novel akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 2008;22(1):147-60
   PubMed Web of Science ®Google Scholar
• Martelli AM, Papa V, Tazzari PL, et al. The novel akt inhibitor perifosine induces apoptosis, cell cycle arrest and synergizes with chemotherapeutic drugs in acute myelogenous leukemia cells by a JNK dependent mechanism - a novel therapeutic approach for leukemia displaying elevated akt signaling. ASH Annu Meet Abstr 2007;110(11):3355
   Google Scholar
• Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318(5848):287-90
   PubMed Web of Science ®Google Scholar
• Dong S, Kang S, Gu TL, et al. 14-3-3 integrates prosurvival signals mediated by the akt and mapk pathways in znf198-fgfr1-transformed hematopoietic cells. Blood 2007;110(1):360-9
   PubMed Web of Science ®Google Scholar
• Rahmani M, Anderson A, Habibi JR, et al. The bh3-only protein bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the pi3k/akt and mek/erk1/2 pathways. Blood 2009;114(20):4507-16
   PubMed Web of Science ®Google Scholar
• Rahmani M, Reese E, Dai Y, et al. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through akt and erk1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 2005;65(6):2422-32
   PubMed Web of Science ®Google Scholar
• David E, Sinha R, Torre C, et al. Combination of farnesyl transferase inhibitor (tipifarnib) with perifosine induces apoptosis through phos-pdk1 in human lymphoma and leukemia cell lines. ASH Annu Meet Abstr 2005;106(11):1488
   Google Scholar
• Mollinedo F, de la Iglesia-Vicente J, Gajate C, et al. In vitro and in vivo selective antitumor activity of edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. Clin Cancer Res 2010;16(7):2046-54
   PubMed Web of Science ®Google Scholar
• Friedman DR, Davis PH, Lanasa MC, et al. Pre-clinical and interim results of a phase ii trial of perifosine in patients with relapsed or refractory chronic lymphocytic leukemia (cll). ASH Annu Meet Abstr 2010;116(21):1842
   Google Scholar
• Guidetti A, Viviani S, Marchiano A, et al. Dual targeted therapy with the akt inhibitor perifosine and the multikinase inhibitor sorafenib in patients with relapsed/refractory lymphomas: Final results of a phase ii trial. ASH Annu Meet Abstr 2012;120(21):3679
   Google Scholar
• Tong Y, Liu YY, You LS, et al. Perifosine induces protective autophagy and upregulation of atg5 in human chronic myelogenous leukemia cells in vitro. Acta Pharmacol Sin 2012;33(4):542-50
   PubMed Web of Science ®Google Scholar
• Bendell JC, Evin TJ, Senzer NN, et al. Results of the x-pect study: a phase iii randomized double-blind, placebo-controlled study of perifosine plus capecitabine (p-cap) versus placebo plus capecitabine (cap) in patients (pts) with refractory metastatic colorectal cancer (mcrc). J Clin Oncol 2012;30(Suppl):abstract LBA3501
   Google Scholar
• Aeterna Zentaris, Inc. Aeterna zentaris to discontinue phase 3 trial in multiple myeloma with perifosine following data safety monitoring board recommendation. Press Release (2013). Available from: http://www.aezsinc.com/en/page.php?p=60&q=550
   Google Scholar
• Bendell JC, Nemunaitis J, Vukelja SJ, et al. Randomized placebo-controlled phase ii trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. J Clin Oncol 2011;29(33):4394-400
   PubMed Web of Science ®Google Scholar
• Richardson PG, Wolf J, Jakubowiak A, et al. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase i/ii trial. J Clin Oncol 2011;29(32):4243-9
   PubMed Web of Science ®Google Scholar
• Martelli AM, Nyakern M, Tabellini G, et al. Phosphoinositide 3-kinase/akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 2006;20(6):911-28
   PubMed Web of Science ®Google Scholar
• Park S, Chapuis N, Tamburini J, et al. Role of the pi3k/akt and mtor signaling pathways in acute myeloid leukemia. Haematologica 2010;95(5):819-28
   PubMed Web of Science ®Google Scholar
• U.S. National Institutes of Health. Available from: www.Clinicaltrials.gov [Last accessed on 15 March 2013]
   Google Scholar
• Cantley LC, Neel BG. New insights into tumor suppression: Pten suppresses tumor formation by restraining the phosphoinositide 3-kinase/akt pathway. Proc Natl Acad Sci U S A 1999;96(8):4240-5
   PubMed Web of Science ®Google Scholar
• Liu P, Cheng H, Roberts TM, et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Dis 2009;8(8):627-44
   PubMed Web of Science ®Google Scholar